secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001104659-25-056378
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma awards CEO $331k and COO $265k in 2024 cash bonuses
----------------------------------------------------------------

- Compensation Committee approved 2024 annual cash bonus of $331,238 for CEO Dr. Michael Myers.
- COO Denise Carter received 2024 annual cash bonus of $264,640.
- Bonuses are consistent with CEO and COO compensation programs approved at Dec 5, 2024 shareholder meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925056378/0001104659-25-056378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925056378/tm2517172d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-056378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer